PATENT CLAIM ANALYSIS

Application Number: 16010945
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-05
Patent Classification: ["514", "262100"]

Abstract:
A novel combination comprising a BTK inhibitor, for example: 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one or a pharmaceutically acceptable salt thereof, and an AKT inhibiting compound, for example: N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which BTK inhibition and/or AKT inhibition is beneficial, e.g., cancer.

Claim (Index 2):
A combination according to  claim 1 , wherein compound (I) is in the form of the free of unsalted compound.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 94.0
- Lexical Diversity: 1.57746
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14456180', '12907759', '12499005', '11617645', '14405317']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.708221071937213
- 35 USC 102 Novelty (BERT): 0.5368009677105298
- Combined Prediction Score: 0.6910790615145447
- Mean Citation Score: 308.102434
- Max Citation Score: 326.1658
- Similarity Product: 182.4173405442596

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test